Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
361 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
Kimball AB, Jemec GBE, Sayed CJ, et al. · Lancet · 2024Randomized Controlled Trial, Multicenter Study
- Prevalence of Hidradenitis Suppurativa: A Systematic Review and Meta-regression Analysis.
Jfri A, Nassim D, O'Brien E, et al. · JAMA Dermatol · 2021Meta-Analysis, Systematic Review
- Efficacy and Safety of Medical Interventions for Moderate to Severe Hidradenitis Suppurativa: A Living Systematic Review and Network Meta-Analysis.
Garg A, Cohn E, Midgette B, et al. · JAMA Dermatol · 2025Systematic Review, Network Meta-Analysis
- Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Kimball AB, Jemec GBE, Alavi A, et al. · Lancet · 2023Randomized Controlled Trial, Clinical Trial, Phase III
- Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
Kimball AB, Okun MM, Williams DA, et al. · N Engl J Med · 2016Clinical Trial, Phase III, Multicenter Study
- Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
Glatt S, Jemec GBE, Forman S, et al. · JAMA Dermatol · 2021Clinical Trial, Phase II, Randomized Controlled Trial
- Efficacy of laser hair removal in hidradenitis suppurativa: A systematic review and meta-analysis.
Shipman WD, Williams MN, Suozzi KC, et al. · Lasers Surg Med · 2024Systematic Review, Meta-Analysis
- Australasian hidradenitis suppurativa management guidelines.
Frew J, Smith A, Penas PF, et al. · Australas J Dermatol · 2025Practice Guideline, Systematic Review
- Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders.
Arnold DD, Yalamanoglu A, Boyman O · Front Immunol · 2022Systematic Review, Research Support, Non-U.S. Gov't
- Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: Results from a phase 2, randomized, placebo-controlled study.
Ackerman LS, Schlosser BJ, Zhan T, et al. · J Am Acad Dermatol · 2025Randomized Controlled Trial, Clinical Trial, Phase II
- Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa.
Kimball AB, Peeva E, Forman S, et al. · NEJM Evid · 2024Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Genomic loci and molecular genetic mechanisms for hidradenitis suppurativa.
Broadaway KA, Sun Q, Edmiston SN, et al. · Br J Dermatol · 2025Meta-Analysis
- IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial.
Ackerman L, Acloque G, Bacchelli S, et al. · Nat Med · 2023Randomized Controlled Trial, Clinical Trial, Phase I
- Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: The SHARPS Randomized Clinical Trial.
Bechara FG, Podda M, Prens EP, et al. · JAMA Surg · 2021Clinical Trial, Phase IV, Multicenter Study
- Menopause and Common Dermatoses: A Systematic Review.
Roster K, Fleshner L, Karatas TB, et al. · Am J Clin Dermatol · 2026Systematic Review
- Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study.
Kirby JS, Okun MM, Alavi A, et al. · J Am Acad Dermatol · 2024Randomized Controlled Trial, Clinical Trial, Phase II
- The Endo-lift Laser (Intralesional 1470 nm Diode Laser) for Dermatological Aesthetic Conditions: A Systematic Review.
Nilforoushzadeh MA, Heidari A, Ghane Y, et al. · Aesthetic Plast Surg · 2024Systematic Review
- Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial.
Kimball AB, Bechara FG, Badat A, et al. · Br J Dermatol · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy and safety of biologics for hidradenitis suppurativa: A network meta-analysis of phase III trials.
Calabrese L, Cartocci A, Rubegni P, et al. · J Eur Acad Dermatol Venereol · 2026Meta-Analysis
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Garcia-Doval I, et al. · Cochrane Database Syst Rev · 2021Research Support, Non-U.S. Gov't, Systematic Review
- The roles of interleukin (IL)-17A and IL-17F in hidradenitis suppurativa pathogenesis: evidence from human in vitro preclinical experiments and clinical samples.
Rastrick J, Edwards H, Ferecskó AS, et al. · Br J Dermatol · 2025Clinical Trial, Phase II
- A genome-wide association meta-analysis links hidradenitis suppurativa to common and rare sequence variants causing disruption of the Notch and Wnt/β-catenin signaling pathways.
Kjærsgaard Andersen R, Stefansdottir L, Riis PT, et al. · J Am Acad Dermatol · 2025Meta-Analysis, Research Support, Non-U.S. Gov't
- Infliximab in hidradenitis suppurativa: A systematic review and meta-analysis.
Shih T, Lee K, Grogan T, et al. · Dermatol Ther · 2022Meta-Analysis, Systematic Review
- Hidradenitis Suppurativa: A Systematic Review and Meta-analysis of Therapeutic Interventions.
Tchero H, Herlin C, Bekara F, et al. · Indian J Dermatol Venereol Leprol · 2019Meta-Analysis, Systematic Review
- Hidradenitis suppurativa and association with stroke: systematic review and meta-analysis.
Phan K, Ng WHS, Lai B, et al. · J Dermatolog Treat · 2022Meta-Analysis, Systematic Review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.